Matthew Starr, MD, and Priya S. Vakharia, MD, deliberate topics including the utility of biomarkers, which second-generation therapies should be considered based on patient characteristics, and when anti-VEGF is not enough.
Switching Agents: Why and When to Incorporate Second-Generation Therapies
Media formats available:
Details
Presenters
Download Workbook
Grantor Statement
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify key risk factors and biomarkers that aid early detection and diagnosis of nAMD
- Analyze factors that prevent translation of nAMD clinical trial treatment efficacy into real-world treatment effectiveness
- Evaluate how advances in nAMD treatments could improve real-world patient outcomes
- Debate the clinical significance of different measures of treatment efficacy in nAMD and their real-world utility
- Discuss key considerations that may influence the selection, timing, and execution of treatment plans for patients with nAMD
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Faculty
Priya S. Vakharia, MD (Chair)
Retina Vitreous Associates of Florida
Palm Harbor and St Petersburg, FL
Matthew Starr, MD
Mayo Clinic
Rochester, MNDisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.Matthew Starr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Evolve, and Gyroscope Therapeutics.
Priya S. Vakharia, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Apellis Pharmaceuticals, Bausch + Lomb, Bayer, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Notal Vision, Novartis, Ocuphire Pharma, Quad-C Management/PRISM Vision, and Regeneron. Grant/Research Support: 4DMT, Alexion, Annexon, Aviceda, Bayer, EyePoint Pharmaceuticals, Genentech, Ionis Pharmaceuticals, Iveric Bio, Janssen, Kodiak Sciences, Novartis, Ocular Therapeutix, ONL Therapeutics, Opthea, Regeneron, RegenxBio, and Unity Biotechnology. Speaker's Bureau: Apellis Pharmaceuticals, Bausch + Lomb, Bayer, Genentech, Heidelberg, Iveric Bio, Novartis, and Regeneron.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Switching Agents Why and When to Incorporate Second Generation Therapies
Show more
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
John W. Kitchens, MD
Sara LeMay, OD
John Kitchens, MD
Sara LeMay, OD
- CME/CE Broadcast Replay
The Comanagement Plan: Elevating Retinal Care Through Unified Vision
1.00 creditSunir J. Garg, MD, FACS, FASRS
John W. Kitchens, MD
Sara LeMay, OD
Charles C. Wykoff, MD, PhD, FACS
Justis P. Ehlers, MD, FASRS
Roger A. Goldberg, MD, MBA
Jennifer, I. Lim, MD, FASRS, FARVO
Ehsan Rahimy, MD
